Jiangsu Joyoung Biopharmaceutical Co., Ltd. is located in the core park of China Medical City (CMC) in Taizhou City, Jiangsu Province. It is a national high-tech enterprise, a Jiangsu provincial “specialized, refined, distinctive, and innovative” small- and medium-sized enterprise, and a key cultivation enterprise in the biopharmaceutical sector, specializing in the research and development, manufacturing, and commercialization of peptide-based drugs, recombinant proteins, and high-end biopharmaceutical preparations. The Company’s core business covers innovative peptide drug development (e.g., GLP-1 analogs, anti-tumor cyclic peptide candidates), as well as integrated supply of high-end generic peptide active pharmaceutical ingredients (APIs) and formulations. Its clients primarily include global biopharmaceutical companies, CDMO partners, and multinational pharmaceutical supply chains. Core capabilities include independently controlled continuous-flow peptide conjugation technology, nanoscale sterile filling processes, and a solid-phase microwave-assisted peptide synthesis platform (SMAP-3000). Single-batch API production capacity reaches the 50-kg level, with impurity profile control precision exceeding ICH Q5A R2 standards. The Company possesses end-to-end Good Manufacturing Practice (GMP)-compliant manufacturing capabilities covering peptide synthesis, lyophilized powder injections, and pre-filled syringes, and provides full-process technical services—from process development and quality research to regulatory filing and submission. The Company holds a Drug Manufacturing License (Category Code: Bh), is certified to ISO 9001:2015 and ISO 13485:2016, and has passed GMP compliance inspections conducted by China’s NMPA, South Korea’s MFDS, and Australia’s TGA across all manufacturing facilities. In 2025, it completed FDA cGMP pre-certification inspection (Report No.: FDA-ORO-2025-0882) and obtained an EDQM Certificate of a Suitability of Monograph to the European Pharmacopoeia (CEP) (R094521). It has established the Jiangsu Provincial Engineering Technology Research Center for Peptide Drugs and holds 37 authorized invention patents; it has led or participated in the formulation of three industry standards. Representative achievements include contract manufacturing and export of glatiramer acetate API for a top-five global insulin manufacturer (cumulative export value exceeding RMB 120 million from 2023 to 2025); undertaking a sub-project under China’s National Science and Technology Major Project “Innovative New Drug Development”—“Key Technology Research on Novel Targeted Cyclic Peptide Conjugates”; and achieving stable delivery of critical products including GLP-1/GIP dual-receptor agonist APIs and anti-fibrotic cyclic peptide APIs. The Company operates a European Regulatory Affairs Center in Frankfurt, Germany (HRB 1234567), and maintains strategic CDMO partnerships with Lonza (Switzerland) and Sun Pharma (India). In 2025, overseas revenue accounted for 41.7% of total revenue, with service coverage spanning all 27 EU member states, the United States, Canada, Australia, and major pharmaceutical markets in Southeast Asia. It supports multiple collaboration models, including technology licensing plus engineering implementation, joint regulatory filings, and cross-border compliant delivery.